A novel human pain insensitivity disorder caused by a point mutation in ZFHX2

Autor: Habib, AM, Matsuyama, A, Okorokov, AL, Santana-Varela, S, Bras, JT, Aloisi, AM, Emery, EC, Bogdanov, YD, Follenfant, M, Gossage, SJ, Gras, M, Humphrey, J, Kolesnikov, A, Le Cann, K, Li, S, Minett, MS, Pereira, V, Ponsolles, C, Sikandar, S, Torres, JM, Yamaoka, K, Zhao, J, Komine, Y, Yamamori, T, Maniatis, N, Panov, KI, Houlden, H, Ramirez, JD, Bennett, DLH, Marsili, L, Bachiocco, V, Wood, JN, Cox, JJ

Publikováno v: Brain

Studies of monogenic heritable pain disorders provide valuable insights into human pain mechanisms. Habib et al. show that a point mutation in the gene ZFHX2 causes an autosomal dominant form of pain insensitivity. Modulating ZFHX2 and/or downstream

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9b3a2fa4dd69969b66d610d59c22aff9
http://hdl.handle.net/11365/1034596

Receptor-specific interactome as a hub for rapid cue-induced selective translation in axons.

Autor: Koppers M; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Cagnetta R; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Shigeoka T; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Wunderlich LC; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom., Vallejo-Ramirez P; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom., Qiaojin Lin J; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Zhao S; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Jakobs MA; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Dwivedy A; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom., Minett MS; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Bellon A; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Kaminski CF; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom., Harris WA; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Flanagan JG; Department of Cell Biology, Harvard Medical School, Boston, United States., Holt CE; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom.

Publikováno v: ELife [Elife] 2019 Nov 20; Vol. 8. Date of Electronic Publication: 2019 Nov 20.

A novel human pain insensitivity disorder caused by a point mutation in ZFHX2.

Autor: Habib AM; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK.; College of Medicine, Member of Qatar Health Cluster, Qatar University, PO Box 2713, Doha, Qatar., Matsuyama A; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Okorokov AL; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Santana-Varela S; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Bras JT; Department of Molecular Neuroscience, Institute of Neurology, University College London, London, WC1N 3BG, UK., Aloisi AM; Department of Medicine, Surgery and Neuroscience, University of Siena, via Aldo Moro, 2, 53100 Siena, Italy., Emery EC; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Bogdanov YD; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Follenfant M; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Gossage SJ; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Gras M; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Humphrey J; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Kolesnikov A; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Le Cann K; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Li S; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Minett MS; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Pereira V; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Ponsolles C; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Sikandar S; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Torres JM; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK.; Department of Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Granada, Granada 18012, Spain., Yamaoka K; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Zhao J; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Komine Y; National Institute for Basic Biology, Okazaki, 444-8585, Japan., Yamamori T; National Institute for Basic Biology, Okazaki, 444-8585, Japan., Maniatis N; Department of Genetics, Evolution and Environment, University College London, London, WC1E 6BT, UK., Panov KI; Medical Biology Centre, School of Biological Sciences, Queen's University Belfast, Belfast, BT9 7BL, UK., Houlden H; Department of Molecular Neuroscience, Institute of Neurology, University College London, London, WC1N 3BG, UK., Ramirez JD; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK., Bennett DLH; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK., Marsili L; Department of Physical Sciences, Earth and Environment, University of Siena, 53100 Siena, Italy., Bachiocco V; Department of Medicine, Surgery and Neuroscience, University of Siena, via Aldo Moro, 2, 53100 Siena, Italy., Wood JN; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK., Cox JJ; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, WC1E 6BT, UK.

Publikováno v: Brain : a journal of neurology [Brain] 2018 Feb 01; Vol. 141 (2), pp. 365-376.

Pharmacological characterisation of the highly Na V 1.7 selective spider venom peptide Pn3a.

Autor: Deuis JR; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Dekan Z; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Wingerd JS; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Smith JJ; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Munasinghe NR; Discipline of Pharmacology, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, 2006, Australia., Bhola RF; Discipline of Pharmacology, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, 2006, Australia., Imlach WL; Discipline of Pharmacology, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, 2006, Australia., Herzig V; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Armstrong DA; School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland, 4072, Australia., Rosengren KJ; School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland, 4072, Australia., Bosmans F; Department of Physiology &Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA., Waxman SG; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut 06510, Rehabilitation Research Center, Veterans Administration Connecticut Healthcare System, West Haven, Connecticut 06516, USA., Dib-Hajj SD; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut 06510, Rehabilitation Research Center, Veterans Administration Connecticut Healthcare System, West Haven, Connecticut 06516, USA., Escoubas P; Venomtech, Sophie-Antipolis, 06560, Valbonne, France., Minett MS; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, UK., Christie MJ; Discipline of Pharmacology, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, 2006, Australia., King GF; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Alewood PF; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Lewis RJ; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia., Wood JN; Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, UK., Vetter I; IMB Centre for Pain Research, Institute for Molecular Bioscience, 306 Carmody Rd (Building 80), The University of Queensland, St Lucia, Queensland, 4072, Australia.; School of Pharmacy, The University of Queensland, Pharmacy Australia Centre of Excellence, 20 Cornwall St, Woolloongabba, Queensland, 4102, Australia.

Publikováno v: Scientific reports [Sci Rep] 2017 Jan 20; Vol. 7, pp. 40883. Date of Electronic Publication: 2017 Jan 20.

The lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain.

Autor: Werdehausen R; Department of Anesthesiology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London, United Kingdom Department of Biochemistry and Molecular Medicine, Institute of Biochemistry, Emil Fischer Center, University of Erlangen-Nürnberg, Erlangen, Germany Department of Anesthesiology, Academic Medical Center, Amsterdam, the Netherlands., Mittnacht S, Bee LA, Minett MS, Armbruster A, Bauer I, Wood JN, Hermanns H, Eulenburg V

Publikováno v: Pain [Pain] 2015 Sep; Vol. 156 (9), pp. 1647-1659.